Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Lucentis: Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

Lucentis - General Information

Lucentis is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Lucentis binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Lucentis has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

 

Pharmacology of Lucentis

Lucentis is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Lucentis binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A).

 

Lucentis for patients

In the days following LUCENTIS administration, patients are at risk of developing endophthalmitis. If the eye becomes red, sensitive to light, painful, or develops a change in vision, the patient should seek immediate care from an ophthalmologist.

 

Lucentis Interactions

Drug interaction studies have not been conducted with LUCENTIS.

LUCENTIS intravitreal injection has been used adjunctively with verteporfin photodynamic therapy (PDT). Twelve of 105 (11%) patients developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (±2 days) after verteporfin PDT.

 

Lucentis Contraindications

Ocular or Periocular Infections

LUCENTIS is contraindicated in patients with ocular or periocular infections.

Hypersensitivity

LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.

 

Additional information about Lucentis

Lucentis Indication: For the treatment of patients with neovascular (wet) age-related macular degeneration. Mechanism Of Action: Lucentis binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and is thought to contribute to the progression of the neovascular form of age-related macular degeneration (AMD). The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Ranibizumab Synonyms: Not Available Drug Category: Not Available Drug Type: Biotech; Approved Other Brand Names containing Ranibizumab: Lucentis; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Approximately 3 days Dosage Forms of Lucentis: Solution Intravitreal Chemical IUPAC Name: Not Available Chemical Formula: C2158H3282N562O681S12 Ranibizumab on Wikipedia: https://en.wikipedia.org/wiki/Ranibizumab Organisms Affected: Humans and other mammals